Bio-techne Corporation Intrinsic Value – MetLife Boosts Investment in Bio-Techne Corporation

☀️Trending News

BIO-TECHNE ($NASDAQ:TECH): Bio-Techne Corporation is a biomedical and biotechnology research and development company based in Minneapolis, Minnesota with a focus on providing instruments, reagents, and other tools for protein and genomic research. Recently, Metropolitan Life Insurance Co. NY (MetLife) has increased their investment in Bio-Techne Corporation, significantly boosting the company’s position. They provide a range of products to support and enhance research across life science disciplines. This includes molecular biology reagents, antibodies, proteins, cell culture media, and other tools for genomic and proteomic research.

Additionally, Bio-Techne Corporation provides contract research and manufacturing services, such as custom antibody production and protein expression. The recent investment from MetLife will provide Bio-Techne with the financial support they need to continue their mission of advancing life science research. This will allow them to focus on increasing their product offerings and expanding their services while continuing to develop new technologies. Through the use of cutting-edge technologies, they can continue to provide innovative solutions for the life science community. The increased investment from MetLife is indicative of Bio-Techne Corporation’s strong performance and the potential for continued growth. With this financial support, they can continue to make advancements in life science research and provide customers with quality products and services.

Price History

MetLife announced on Wednesday that it has boosted its investment in Bio-Techne Corporation. The stock opened at $77.0 and closed at $76.6, representing a 1.0% decrease from the previous closing price of 77.4. This news comes as investors have been taking a closer look at the biotechnology sector in recent months, with Bio-Techne Corporation being one of the stocks to watch.

The company is a global leader in developing and manufacturing biotechnology products for research and clinical diagnostic use, and its products are used in a variety of industries. With MetLife’s increased investment in the company, Bio-Techne Corporation could potentially benefit from an even wider market reach. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bio-techne Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bio-techne Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bio-techne Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Bio-techne Corporation are shown below. More…

Analysis – Bio-techne Corporation Intrinsic Value

We at GoodWhale conducted an analysis of BIO-TECHNE CORPORATION‘s wellbeing. After extensive research, our proprietary Valuation Line suggested that the intrinsic value of BIO-TECHNE CORPORATION shares is around $103.2. However, currently, BIO-TECHNE CORPORATION’s stock is trading at $76.6, 25.8% below its true value. This represents an opportunity to invest in a well-respected company at a discounted price. We highly recommend this opportunity to all investors. More…

Peers

In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.

– Proteomics International Laboratories Ltd ($ASX:PIQ)

Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.

– AEterna Zentaris Inc ($TSX:AEZS)

Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.

– AXIM Biotechnologies Inc ($OTCPK:AXIM)

AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.

The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.

The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.

Summary

Bio-Techne Corporation (formerly Techne Corporation) is a biotechnology company specializing in developing and supplying innovative life science products and tools to researchers and clinicians. The company produces a wide range of products including molecular diagnostics, antibodies, proteins, and peptides. The company focuses on developing advanced technology to improve research discovery and clinical treatments. In addition to its product offerings, Bio-Techne also provides custom services for specific needs in the life science industry.

Recent analysis of Bio-Techne’s stock suggests that there is increasing investor interest in the company, evidenced by Metropolitan Life Insurance Co. NY increasing their position in the company. With strong product offerings, backed by research and development, and a growing investor base, Bio-Techne looks to be a promising investment opportunity for investors.